[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100543583":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":26,"centralContacts":29,"locations":37,"responsibleParty":148,"collaborators":10,"id":150,"slug":151,"hasResults":152,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":10,"eligibilityCriteria":156,"healthyVolunteers":152,"sex":157,"minAge":10,"maxAge":10,"enrollmentInfo":158,"targetDuration":10,"studyType":161,"phases":10,"briefSummary":162,"conditions":163,"keywords":10,"overallStatus":57,"whyStopped":10,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":176},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Participants treated with idecabtagene vicleucel",null,[12],"Biological: Idecabtagene vicleucel",{"label":14,"type":10,"description":10,"interventionNames":15},"Participants treated with lisocabtagene maraleucel",[16],"Biological: Lisocabtagene maraleucel",[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":10},"BIOLOGICAL","Idecabtagene vicleucel","As per product label",[9],{"type":19,"name":24,"description":21,"armGroupLabels":25,"otherNames":10},"Lisocabtagene maraleucel",[14],[27],{"name":5,"affiliation":5,"role":28},"STUDY_DIRECTOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"BMS Study Connect Contact Center www.BMSStudyConnect.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":36,"role":32,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[38,55,70,83,94,109,124,133],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Local Institution - 0016","NOT_YET_RECRUITING","Portland","Oregon","97239-3098","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-122.67621,45.52345,{"lat":50,"lon":49},[53],{"name":54,"role":32,"phone":10,"phoneExt":10,"email":10},"Site 0016",{"facility":56,"status":57,"city":58,"state":59,"zip":60,"country":44,"countryCode":45,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Ut Southwestern","RECRUITING","Dallas","Texas","75235",{"type":47,"coordinates":62},[63,64],-96.80667,32.78306,{"lat":64,"lon":63},[67],{"name":68,"role":32,"phone":69,"phoneExt":10,"email":10},"Larry Anderson, Site 0008","214-648-5906",{"facility":71,"status":57,"city":72,"state":73,"zip":74,"country":44,"countryCode":45,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Huntsman Cancer Institute at the University of Utah","Salt Lake City","Utah","84112",{"type":47,"coordinates":76},[77,78],-111.89105,40.76078,{"lat":78,"lon":77},[81],{"name":82,"role":32,"phone":10,"phoneExt":10,"email":10},"Lauren Lee, Site 0010",{"facility":84,"status":85,"city":86,"state":87,"zip":88,"country":44,"countryCode":45,"cosmosGeoPoint":89,"geoPoint":93,"contacts":10},"Local Institution - 0004","WITHDRAWN","Madison","Wisconsin","53792",{"type":47,"coordinates":90},[91,92],-89.40123,43.07305,{"lat":92,"lon":91},{"facility":95,"status":57,"city":96,"state":10,"zip":97,"country":98,"countryCode":99,"cosmosGeoPoint":100,"geoPoint":104,"contacts":105},"Universitaetsklinikum Essen (AoR)","Essen","45147","Germany","DE",{"type":47,"coordinates":101},[102,103],7.01228,51.45657,{"lat":103,"lon":102},[106],{"name":107,"role":32,"phone":108,"phoneExt":10,"email":10},"Bastian von Tresckow, Site 0001","+491631751277",{"facility":110,"status":57,"city":111,"state":112,"zip":113,"country":114,"countryCode":115,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Toyokawa City Hospital","Toyokawa","Aichi-ken","442-8561","Japan","JP",{"type":47,"coordinates":117},[118,119],137.4,34.81667,{"lat":119,"lon":118},[122],{"name":123,"role":32,"phone":10,"phoneExt":10,"email":10},"Akimi Kawai, Site 0012",{"facility":125,"status":85,"city":126,"state":126,"zip":127,"country":114,"countryCode":115,"cosmosGeoPoint":128,"geoPoint":132,"contacts":10},"Local Institution - 0003","Kumamoto","8608556",{"type":47,"coordinates":129},[130,131],130.69181,32.80589,{"lat":131,"lon":130},{"facility":134,"status":57,"city":135,"state":10,"zip":136,"country":137,"countryCode":138,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"Kantonsspital Aarau","Aarau","5001","Switzerland","CH",{"type":47,"coordinates":140},[141,142],8.04422,47.39254,{"lat":142,"lon":141},[145],{"name":146,"role":32,"phone":147,"phoneExt":10,"email":10},"Sabine Veronika Gerull, Site 0002","+41628386505",{"type":149,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100543583","transgene-assay-testing-service-of-tumor-samples-from-patients-who-received-a-bristol-myers-squibb-manufactured-gene-modified-cell-therapy-and-have-a-qualifying-second-primary-malignancy-100543583",false,"NCT06357754","Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy","Protocol for Transgene Assay Service","Inclusion Criteria:\n\n* Participant has received a commercially available Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.\n* Participant has received a commercially available BMS manufactured GMCT in a clinical trial or other investigational setting (including non-conforming product) for which there is no testing protocol in place for that trial or investigational setting and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.\n\nExclusion Criteria:\n\n* Participant is actively participating in a clinical trial where information and sample collection is being conducted under that clinical trial.\n* Participant has not received a BMS manufactured GMCT or has not been diagnosed with a qualifying second primary malignancy.","ALL",{"count":159,"type":160},50,"ESTIMATED","OBSERVATIONAL","The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.",[164,165,166],"Non-Hodgkin Lymphoma","Chronic Lymphocytic Leukaemia","Multiple Myeloma","2026-01-21",{"date":169,"type":170},"2026-01-22","ACTUAL",{"date":172,"type":170},"2023-10-06",{"date":174,"type":160},"2038-10-06",{"name":5,"class":6},8]